Wysa
Free-to-talk AI wellbeing chatbot with CBT tools and NHS intake
Overview
Wysa is an AI mental wellbeing companion from Touchkin eServices of Bengaluru that responds to how users feel and suggests CBT, mindfulness and other evidence-based exercises. Talking to it is free; Premium unlocks a larger tool library and human coaching costs extra. Wysa also sells intake, wellbeing-hub and hybrid therapy platforms to health systems, insurers and employers, including NHS Talking Therapies services.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 14 Oct 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- Talking to Wysa AI
- Tools offered within conversations
- A much wider selection of tools
- Tool library accessible directly as well as in conversation
- 30-minute live text sessions with a Wysa coach
- Same assigned coach each time
- Users aged 18 and over
- Gateway digital intake and referral
- Navigator wellbeing hub
- Copilot hybrid digital and human therapy platform
Use cases
What you can produce with Wysa
- Anonymous AI conversations that help users reflect on how they feel, at any hour
- Suggested CBT, mindfulness and solution-focused exercises matched to the conversation
- Signposting to crisis resources when distress is detected
- Text-based sessions with a human wellbeing coach (paid)
- Digital self-referral and intake with clinical summaries for NHS Talking Therapies services
- A hybrid therapy platform letting clinicians support patients between sessions
ASEAN Perspective
Wysa in Southeast Asia
Wysa has genuine roots in South Asia — founded in Bangalore, with multilingual support that includes Hindi, Marathi, and other Indian regional languages, and a Singapore national health cluster pilot during COVID-19 (2020–2022). However, dedicated localisation for Southeast Asian markets (Bahasa Indonesia, Filipino, Thai, Vietnamese) remains limited, and regional enterprise pricing has not been publicly disclosed, making B2B adoption in ASEAN health systems uncertain. The platform's recognition at the India AI Impact Summit 2026 reinforces its APAC credibility, but ASEAN users outside India and Singapore will find both language coverage and local clinical partnerships thinner than in the UK or US markets.
Wysa is one of the better-evidenced mental wellbeing chatbots: free to talk to, built on CBT and mindfulness techniques, and deployed for intake inside NHS Talking Therapies services and by Singapore's Ministry of Health. Its FDA Breakthrough Device Designation is real but narrow, a 2022 designation for chronic pain with depression and anxiety, not an approval.
It is for low mood, stress and anxiety, not crises, and Wysa says so. Premium at $74.99 a year is reasonable; human coaching costs much more.
What we found
Wysa is an AI mental health companion built by Touchkin eServices, the Bengaluru company of Jo Aggarwal and Ramakant Vempati, with offices in Boston and London. The idea dates from 2016. A user talks to a penguin-fronted chatbot, which listens, reflects and suggests exercises drawn from cognitive behavioural therapy, mindfulness and similar approaches. Wysa says its replies come from a mix of rule-based scripts and large language model prompts, and that it is not a crisis service and gives no clinical advice.
The phrase "FDA Breakthrough" needs its scope. In May 2022 the US FDA granted Breakthrough Device Designation to an AI-led conversational CBT agent from Wysa for adults with chronic musculoskeletal pain and associated depression and anxiety. A designation buys closer contact with the agency during development; it is not approval or clearance, and it covers that use, not the consumer app as a whole.
The larger business is now selling to health systems. In NHS Talking Therapies services Wysa handles self-referral and intake, and the company reports more than 185,000 clients supported, a 91% referral completion rate and 30 minutes saved per assessment; those are Wysa's figures. It names Singapore's Ministry of Health and the insurer Vitality among deployments. In 2025 it acquired April Health, which brings AI support into US primary care under the collaborative care model, and Kins, a physical therapy provider. Vendor user counts vary by page, from six million to eleven million.
For individuals, talking to Wysa is free, including the tools offered in conversation. Premium opens a much larger tool library; on the US App Store it is $74.99 a year or $19.99 a month, and human guided support with a coach costs extra, $79.99 a month. The App Store listing showed 4.8 from about 24,000 ratings, read 14 October 2026. Anyone in crisis should contact local emergency services rather than an app.
Compiled by RECATOOLS from public sources: vendor documentation and pricing, code repositories and published reporting.
Notable facts
- Wysa's AI penguin mascot was deliberately designed to feel non-threatening — early user research found people disclosed more to an animal persona than to a human avatar.
- Over 91% of patients who used Wysa's NHS Digital Referral Assistant completed their self-referral — a 25-percentage-point improvement over previous baseline rates.
- Wysa received its FDA Breakthrough Device Designation in May 2022, making it one of the first AI mental health chatbots to reach that regulatory milestone.
- Swiss Re co-created Wysa Assure specifically as an insurance-embedded mental health product — a first-of-kind model that MassMutual adopted in October 2024.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Wysa's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Wysa unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Wysa directly →
Spotted something out of date? Suggest an update →
More in Healthcare
